Human immunodeficiency virus [HIV] disease resulting in other specified diseases

AB1_OTHER_DISEASE

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — B22 Cause of death: ICD-10 — B22 2 out of 7 registries used, show all original rules.	19
4. Check minimum number of events None	19
5. Include endpoints None	19
6. Filter based on genotype QC (FinnGen only)	19

Control definitions (FinnGen only)

Control exclude: AB1_HIV

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF5

NAME	AB1_OTHER_DISEASE
CONTROL_EXCLUDE	AB1_HIV
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	B22
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	B22
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Human immunodeficiency virus [HIV] disease resulting in other specified diseases based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	165	53	107
Only index persons	125	43	82
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	45.77	46.32	45.82
Only index persons	46.04	44.51	46.84

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	19	6	13
Unadjusted period prevalence (%)	0.00	0.00	0.01
Median age at first event (years)	49.76	47.20	50.94

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3017143) Hepatitis C virus Ab [Presence] in Serum

12.81

5.92

4.3

1.5

—

(3045462) Protein/Creatinine [Ratio] in Urine

+∞

5.44

4.8

0.0

24.4

—

g/mol

—

(3019832) Treponema pallidum Ab [Presence] in Serum

14.24

5.28

2.2

1.5

—

(42870588) Differential panel, method unspecified - Blood

8.28

4.50

17.5

5.7

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

11.44

3.95

5.4

1.6

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

5.44

3.14

1.7

1.5

1.4

mmol/l

0.23

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

5.41

2.94

4.2

3.6

—

(36304419) Bacteria [Presence] in Urine

4.80

2.80

4.5

3.0

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

9.14

2.72

2.4

1.0

—

(3000494) Fungus identified in Specimen by Culture

5.85

2.66

1.6

1.4

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

7.97

2.53

3.0

1.0

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

4.64

2.22

1.1

1.4

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

5.73

2.08

1.4

2.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

3.43

1.80

5.5

3.7

—

(3015736) pH of Urine

3.53

1.80

5.1

3.9

—

(40758558) Short blood count panel - Blood

3.35

1.71

21.3

8.0

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

3.19

1.71

3.6

8.4

1.2

mmol/l

0.03

(3021589) Normoblasts [#/volume] in Blood

3.20

1.64

24.8

11.4

0.0

e9/l

0.00

(3012544) pH of Venous blood

4.12

1.63

2.0

5.9

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

3.21

1.58

5.1

2.8

11.3

184.5

ng/l

—

(3042936) Bacteria identified in Isolate by Culture

3.17

1.43

1.5

1.7

—

(3032080) INR in Blood by Coagulation assay

2.89

1.40

18.1

9.2

1.3

inr

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

2.72

1.27

24.1

14.9

2.8

4.5

e9/l

3.22

(3037467) Urinalysis macro (dipstick) panel - Urine

2.79

1.25

9.2

4.1

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

2.57

1.15

1.9

1.6

2.5

1.0

mg/l

—

(40768804) Tissue Pathology biopsy report

2.40

1.03

3.3

1.6

—

(3021960) Folate [Moles/volume] in Serum or Plasma

2.45

0.97

1.0

1.7

15.5

24.1

nmol/l

—

(3023368) Bacteria identified in Blood by Culture

2.05

0.79

4.3

5.7

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

2.34

0.79

1.6

2.0

30.2

29.0

—

(3009508) Creatinine [Moles/volume] in Urine

1.92

0.72

5.3

2.7

10.1

9.3

mmol/l

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

2.06

0.72

2.0

519.6

522.5

pmol/l

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

0.00

0.64

0.0

4.2

—

104.6

—

(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma

0.00

0.64

0.0

4.2

—

26.9

—

(3013707) Erythrocyte sedimentation rate by Westergren method

117

1.74

0.48

6.4

3.6

12.1

11.7

mm/h

0.05

107

(3026008) Bacteria identified in Urine by Culture

1.58

0.43

2.6

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.43

0.0

1.4

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.42

0.0

2.1

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

1.47

0.36

4.3

1.9

97.4

129.2

u/l

—

(3044889) 12 lead EKG panel

118

1.70

0.34

3.7

3.5

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

1.52

0.27

2.2

3.9

1696.2

2323.3

ng/l

—

(3019225) pH of Specimen

0.00

0.22

0.0

10.1

—

(3020961) Endomysium IgA Ab [Titer] in Serum

0.00

0.22

0.0

1.1

—

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

0.00

0.22

0.0

4.1

—

4.8

—

(3022621) pH of Urine by Test strip

0.00

0.22

0.0

1.4

—

(3014007) Fractional oxyhemoglobin in Arterial blood

0.00

0.22

0.0

3.8

—

94.9

—

(4010399)

0.00

0.22

0.0

1.4

—

(3020891) Body temperature

0.00

0.22

0.0

4.0

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

0.00

0.22

0.0

3.6

—

0.7

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

0.00

0.22

0.0

3.6

—

1.4

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.22

0.0

1.7

—

(3022145) Colonoscopy Study observation

0.00

0.21

0.0

1.6

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.12

0.10

5.4

3.1

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

0.77

0.10

5.6

5.3

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

106

0.88

0.09

3.1

2.5

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3043409) Potassium [Moles/volume] in Arterial blood

0.00

0.0

2.7

—

4.1

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.4

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.1

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.0

3.1

—

1.2

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

1.4

—

218.1

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

0.00

0.0

3.6

—

2.1

—

(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood

0.00

0.0

4.0

—

47.2

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

0.00

0.0

1.0

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

0.00

0.0

2.6

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.0

4.6

—

24.5

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

0.00

0.0

2.8

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

0.00

0.0

3.2

—

520.2

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.3

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.0

1.3

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

0.93

0.00

5.8

3.6

—

(3022313) Gas panel - Capillary blood

0.00

0.0

5.0

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.0

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.00

0.0

1.2

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

0.0

1.2

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

0.0

1.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_OTHER_DISEASE and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have AB1_OTHER_DISEASE.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: AB1_OTHER_DISEASE – Human immunodeficiency virus [HIV] disease resulting in other specified diseases

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Human immunodeficiency virus [HIV] disease resulting in other specified diseases

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints